BioCentury | Jan 15, 2021
Finance

A maturing mid-cap sector could keep funds flowing into biotech

While it’s too early to say whether 2020’s record year of fund-raising constitutes a “new normal,” there’s consensus among buysiders and bankers that a cheap money environment will continue in 2021 as...
BioCentury | Jan 15, 2021
Finance

Investors’ picks & access to capital in 2021: a BioCentury podcast

Targeted cancer programs are catching the eyes of buysiders as they kick off the New Year with a positive outlook for the capital markets. On the latest BioCentury This Week podcast, BioCentury editors discuss investor...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with...
BioCentury | Jan 13, 2021
Politics, Policy & Law

BIO, PhRMA ‘pause’ political giving

In the wake of the storming of the U.S. Capitol, BIO and PhRMA have joined other trade associations and U.S. companies in reassessing their criteria for making political contributions. The biopharma trade associations have not...
BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

More than a decade after Kymab was first backed by the Wellcome Trust to derive drug candidates from an engineered mouse model, the company has accepted a $1.1 billion takeout offer from Sanofi that closely...
BioCentury | Jan 11, 2021
Politics, Policy & Law

Truth and facts matter. Say it out loud: Editor’s Commentary

First they came for the climate scientists, and I did not speak out because I wasn’t a climate scientist. Then they came for the mask-wearers, and I did not speak out because I was...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

After a quiet first nine months, Paris-based VC Jeito ended 2020 with a trio of investments and a €50 million infusion by Sanofi. And while all three venture plays were in early-stage gene and cell...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Jan 9, 2021
Tools & Techniques

What DeepMind’s leap means for structure-based drug developers

The step change in protein folding prediction pioneered by Alphabet’s DeepMind stands to widen the funnel of targets tackled with structure-based platforms, including newly discovered proteins from...
BioCentury | Jan 8, 2021
Product Development

Caplan sees a host of bioethical turning points coming out of the pandemic

The reckoning that will come after the pandemic will see broad if not tectonic shifts in drug development, from clinical trial conduct to scientific publishing, according to bioethicist Arthur Caplan....
Items per page:
1 - 10 of 7319